Publication First in Human study
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics.
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli
First patent granted in Japan
LiGalli raises €6.6 million in Series B
The LiGalli press release can be found here.
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
LiGalli receives the International Life Sciences Award 2021
The basic MedRing patent is granted in China
Stunning results LiGalli first in human study
LiGalli receives the International Life Sciences Award 2020
See an image of the award here. Read the interview with LiGalli's CEO here.
The MedRing Alpha 1.0 is ready
The first in-human trials will start shortly.
LiGalli raises €6 million
The LiGalli press release can be found here. The Demcon press release can be found here.
The basic MedRing patent is granted
First in the EU, later also in the US
The MedRing functional model is ready
The Dutch Government awards LiGalli the MIT subsidy
We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).
